FDA OKs Teva migraine med autoinjector

Teva Pharmaceuticals USA announced that the U.S. Food and Drug Administration has approved its autoinjector device for Ajovy (fremanezumab-vfrm) injection.

The Ajovy autoinjector, which is a calcitonin gene-related peptide antagonist indicated for the preventive treatment of migraine in adults, is expected to be available to patients in the coming months. The drug is the only FDA-approved anti-CGRP that offers a quarterly (675 mg) or monthly (225 mg) dosing option.

Read the full Teva release